Announcement of Hisilicon on the first clinical approval of hsk3486, a new chemical drug of category 1.1

Securities code: 002653 securities abbreviation: hysic Announcement No.: 2016-017 announcement of hysic Pharmaceutical Group Co., Ltd on obtaining the first class 1.1 clinical approval of new chemical drugs the company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without any false record, misleading statement or major omission Sichuan hisilica Pharmaceutical Co., Ltd., a subsidiary of hisilica Pharmaceutical Group Co., Ltd (hereinafter referred to as "the company"), recently received the approval of the State Food and Drug Administration (hereinafter referred to as "CFDA") for the issuance of category 1.1 "hsk3486" chemicals The company will carry out the follow-up clinical trials as soon as possible Hsk3486 is a general anaesthetic for injection It is the first new molecular entity drug independently developed by the company It has applied for patents from more than 20 countries, including China, the United States, the European Union and Japan This product has completed the phase I clinical trial in Australia, involving 92 subjects in total The research results show that hsk3486 has the advantages of higher potency (the potency is 4-5 times of propofol at the same dose), less effect on blood pressure, no obvious injection pain and so on compared with propofol, the most widely used anesthetic in clinical According to IMS data, propofol's global sales volume in 2015 was about US $1.069 billion, which is the trump brand product in the field of anesthesia and sedation, mainly used in the fields of anesthesia induction and maintenance, painless abortion and painless gastroscopy, and the field of ICU sedation Therefore, it is expected that hsk3486 will replace propofol in some markets if it can be successfully listed in the future, with a bright sales prospect Hsk3486 is the company's first chemical innovative drug with independent intellectual property rights, which has obtained CFDA clinical trial approval It is also a milestone for the company to upgrade from generic drug research and development to innovative drug research and development Please make rational investment and pay attention to investment risks It is hereby announced Board of directors of HISCO Pharmaceutical Group Co., Ltd March 9, 2016